Abstract

Acute coronary syndrome (ACS) is a very common cause of hospitalizations worldwide each year. In the past decades biomarkers have become an indispensable tool for diagnosis, risk stratification and prognosis of cardiovascular disease, including ACS. Despite Troponin is considered the gold standard in diagnosis of ACS, several molecules have been investigated to identify predictive biomarkers of prognosis. Among these, Gal-3 has emerged as a promising prognostic marker. It has a pivotal role in inflammation and fibrosis. Both experimental and clinical studies have shown Gal-3 is an independent predictor of all-cause mortality, cardiovascular death and occurrence of HF following ACS. This article reviews the literature data regarding the role of Galectin-3 in ACS setting.
Lingua originaleEnglish
pagine (da-a)797-803
Numero di pagine7
RivistaClinical Biochemistry
Volume50
Stato di pubblicazionePublished - 2017

Fingerprint

Galectin 3
Biomarkers
Acute Coronary Syndrome
Troponin
Molecules
Hospitalization
Fibrosis
Cardiovascular Diseases
Inflammation
Mortality

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry

Cita questo

@article{9111d40a9b7c410a8d4648abd13aa200,
title = "Galectin-3 in acute coronary syndrome",
abstract = "Acute coronary syndrome (ACS) is a very common cause of hospitalizations worldwide each year. In the past decades biomarkers have become an indispensable tool for diagnosis, risk stratification and prognosis of cardiovascular disease, including ACS. Despite Troponin is considered the gold standard in diagnosis of ACS, several molecules have been investigated to identify predictive biomarkers of prognosis. Among these, Gal-3 has emerged as a promising prognostic marker. It has a pivotal role in inflammation and fibrosis. Both experimental and clinical studies have shown Gal-3 is an independent predictor of all-cause mortality, cardiovascular death and occurrence of HF following ACS. This article reviews the literature data regarding the role of Galectin-3 in ACS setting.",
keywords = "Acute coronary syndrome; AMI; Galectin-3; Heart failure; Myocardial infarction; Prognosis; Acute Coronary Syndrome; Atherosclerosis; Biomarkers; Galectin 3; Heart Failure; Humans; Myocardial Infarction; Prognosis; Evidence-Based Medicine; Clinical Biochemistry",
author = "Viviana Bazan and Marcello Ciaccio and Concetta Scazzone and Giulia Bivona and Chiara Bellia and {Lo Sasso}, Bruna and Luisa Agnello and Marcello Ciaccio",
year = "2017",
language = "English",
volume = "50",
pages = "797--803",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Galectin-3 in acute coronary syndrome

AU - Bazan, Viviana

AU - Ciaccio, Marcello

AU - Scazzone, Concetta

AU - Bivona, Giulia

AU - Bellia, Chiara

AU - Lo Sasso, Bruna

AU - Agnello, Luisa

AU - Ciaccio, Marcello

PY - 2017

Y1 - 2017

N2 - Acute coronary syndrome (ACS) is a very common cause of hospitalizations worldwide each year. In the past decades biomarkers have become an indispensable tool for diagnosis, risk stratification and prognosis of cardiovascular disease, including ACS. Despite Troponin is considered the gold standard in diagnosis of ACS, several molecules have been investigated to identify predictive biomarkers of prognosis. Among these, Gal-3 has emerged as a promising prognostic marker. It has a pivotal role in inflammation and fibrosis. Both experimental and clinical studies have shown Gal-3 is an independent predictor of all-cause mortality, cardiovascular death and occurrence of HF following ACS. This article reviews the literature data regarding the role of Galectin-3 in ACS setting.

AB - Acute coronary syndrome (ACS) is a very common cause of hospitalizations worldwide each year. In the past decades biomarkers have become an indispensable tool for diagnosis, risk stratification and prognosis of cardiovascular disease, including ACS. Despite Troponin is considered the gold standard in diagnosis of ACS, several molecules have been investigated to identify predictive biomarkers of prognosis. Among these, Gal-3 has emerged as a promising prognostic marker. It has a pivotal role in inflammation and fibrosis. Both experimental and clinical studies have shown Gal-3 is an independent predictor of all-cause mortality, cardiovascular death and occurrence of HF following ACS. This article reviews the literature data regarding the role of Galectin-3 in ACS setting.

KW - Acute coronary syndrome; AMI; Galectin-3; Heart failure; Myocardial infarction; Prognosis; Acute Coronary Syndrome; Atherosclerosis; Biomarkers; Galectin 3; Heart Failure; Humans; Myocardial Infarction; Prognosis; Evidence-Based Medicine; Clinical Biochem

UR - http://hdl.handle.net/10447/249837

UR - http://www.elsevier.com/locate/clinbiochem

M3 - Article

VL - 50

SP - 797

EP - 803

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

ER -